Tokyo-based Daiichi Sankyo has obtained an exclusive license to develop and commercialize AstraZeneca’s influenza vaccine Flumist Quadrivalent in Japan.

The nasal spray, a live attenuated vaccine that contains four protective strains, is now being prepared for regulatory submission in the nation.

As part of the new deal, Daiichi receives full responsibility for the future development and commercialization of the vaccine in its domestic market and ownership of the marketing authorization if approved.

Although financial specifics were not revealed, the companies said Daiichi will pay an up-front fee, along with subsequent development milestones and sales-related payments after the launch.

London-based AstraZeneca’s flu vaccine was approved in the U.S. in early 2012.